Navigation Links
Reportlinker Adds Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants
Date:6/27/2011

NEW YORK, June 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Product Profiles: Multiple Sclerosis - Gilenya raises bar for new market entrants

http://www.reportlinker.com/p0564421/Product-Profiles-Multiple-Sclerosis---Gilenya-raises-bar-for-new-market-entrants.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Introduction

Beginning with the recent approval of Gilenya (Novartis; fingolimod), MS patients are experiencing the arrival of more effective and less invasive treatment options after numerous years of limited therapeutic options. As competition intensifies, the need for less invasive modes of administration will be met and new drugs will have to compete on other factors, such as efficacy.

Features and benefits

* Understand Datamonitor's independent appraisal of marketed brands and key pipeline agents indicated for treating multiple sclerosis.

* Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes.

* Assessment of the strengths, weaknesses, opportunities, and threats for key marketed and pipeline therapies.

* Review of important clinical developments for key pipeline agents with analysis of the latest clinical trial data.

* Determine to what extent current and future therapies satisfy the main clinical unmet needs in multiple sclerosis treatment.

Highlights

Datamonitor's recent survey reveals that US neurologists prescribe Gilenya because of its strong efficacy in treatment resistant patients as well as its convenient oral mode of administration. However, long term cancer and infection risk remain the main concerns.

The multiple sclerosis market has been lucrative for drug companies over the last decade with limited competition and periodic price increases. However, as this dynamic is changing with increased competition, existing players are expanding their portfolios with new and improved therapies.

Monoclonal antibodies have demonstrated potent efficacy in Phase II trials, surpassing all existing therapies. However, excitement is tempered with safety concerns that include risk of malignancy and severe infections. Still, as seen with Tysabri, impressive efficacy may outweigh the risks for more severe multiple sclerosis patients.

Your key questions answered

* How well do agents in late-stage development for multiple sclerosis compare to one another and the current standard of care?

* What is the most promising treatment in development for multiple sclerosis?

* How do US neurologists perceive Gilenya and key pipeline agents as new treatments of multiple sclerosis?

Executive Summary

Strategic scoping and focus

Datamonitor key findings

Related reports

OVERVIEW

Catalyst

Summary

MARKET OVERVIEW

Product overview

Datamonitor's assessment summary

MARKETED PRODUCT PROFILES

Gilenya (fingolimod; Novartis/Mitsubishi Tanabe Pharma)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Product positioning

Physician perception of Gilenya

Clinical and commercial attractiveness

Avonex (interferon beta-1a; Biogen Idec)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Product positioning

Clinical and commercial attractiveness

Rebif (interferon beta-1a; Merck Serono)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Product positioning

Clinical and commercial attractiveness

Betaseron (interferon beta-1b; Bayer Schering)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Product positioning

Clinical and commercial attractiveness

Extavia (interferon beta-1a; Novartis)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Product positioning

Clinical and commercial attractiveness

Copaxone (glatiramer acetate; Teva)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Product positioning

Clinical and commercial attractiveness

Tysabri (natalizumab; Biogen Idec/Elan)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Product positioning

Clinical and commercial attractiveness

Ampyra (dalfampridine; Acorda Therapeutics/Biogen Idec/Elan)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Product positioning

Clinical and commercial attractiveness

Sativex (nabiximols; GW Pharmaceuticals)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Product positioning

Clinical and commercial attractiveness

Other marketed drugs for multiple sclerosis

Novantrone (mitoxantrone; Merck Serono)

PIPELINE PRODUCT PROFILES

Movectro (cladribine; Merck Serono)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Physician perception of Movectro

Clinical and commercial attractiveness

Monthly Avonex (PEGylated interferon beta-1a; Biogen Idec)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Physician perception of monthly Avonex

Clinical and commercial attractiveness

BG-12 (dimethyl fumarate; Biogen Idec)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Physician perception of BG-12

Clinical and commercial attractiveness

Laquinimod (Teva)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Physician perception of laquinimod

Clinical and commercial attractiveness

Daclizumab (Biogen Idec/Abbott)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Physician perception of daclizumab

Clinical and commercial attractiveness

Teriflunomide (HMR1726; Sanofi)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Physician perception of teriflunomide

Clinical and commercial attractiveness

Lemtrada (alemtuzumab; Genzyme/Bayer Schering)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Physician perception of Lemtrada

Clinical and commercial attractiveness

Ocrelizumab (R15-2477; Roche/Biogen Idec)

Drug profile

Development overview

SWOT analysis

Physician perception of ocrelizumab

Satisfaction of unmet needs

Clinical and commercial attractiveness

Other drugs in development for multiple sclerosis

Tovaxin (Opexa Therapeutics)

BHT-3009 (Bayhill Therapeutics)

Neurovax (Immune Response BioPharma)

Firategrast (GlaxoSmithKline)

ATL1102 (Isis Pharmaceuticals/Antisense Therapeutics)

BAF312 (Novartis)

Ponesimod (R-3477; Actelion)

ONO-4641 (Ono Pharmaceuticals)

Arzerra (ofatumumab; Genmab/GlaxoSmithKline)

LY2127399 (Eli Lilly)

Pleneva (BGC-20-0134; BTG)

IPX056 (baclofen controlled release; Impax Laboratories)

MCT-125 (lofepramine and L-phenylalanine; Multicell Technologies)

BIBLIOGRAPHY

Journal papers

Websites

Other sources

Datamonitor reports

APPENDIX A

Datamonitor drug assessment scorecard

Physician research methodology

Physician sample breakdown

The survey questionnaire

Introduction

Section 1: Unmet Needs

Section 2: Influencing factors on prescribing

Section 3: New therapies entering Multiple Sclerosis

Demographics

APPENDIX B

Market definition

PharmaVitae Explorer database

Contributing experts

Conferences attended

Report methodology

To order this report:

Pathology Industry: Product Profiles: Multiple Sclerosis - Gilenya raises bar for new market entrants

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, the ... unveiled a new store design to enhance the ... healthier food, health-focused products and expanded beauty selections ... help customers discover new offerings. Together with its ... evolution of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces the ... instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ... hour rated lamps utilize the existing electronic ballast, saving labor and maintenance costs. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back ... joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified ... The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood ... to the labor and delivery team at Women’s Hospital at Renaissance in Edinburg for ... birth at the hospital and decide to donate. , “Women’s Hospital at Renaissance ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early ... substantially improve drug safety and minimize the cost of development. In this webinar, ... inhibition using cell lines and for cardiac toxicity using induced pluripotent stem cells ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Bill Howe ... industry in the coastal communities. After Tina Howe joined the team, the Bill Howe ... employees, honest services at affordable rates, and giving back to the San Diego community ...
Breaking Medicine News(10 mins):